Nefazodone: A better tolerated option than TCAs for major depression

Drugs and Therapy Perspectives

Volumn 10, Issue 8, 1997, Pages 1-7

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; IMIPRAMINE; NEFAZODONE; PAROXETINE; SERTRALINE;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN;

EID: 0030826588     PISSN: 11720360     EISSN: None     Source Type: Journal    
DOI: 10.2165/00042310-199710080-00001     Document Type: Article

References (23)

1. Blazer DG, Kessler RC, McGonagle KA, et al. The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survey. Am J Psychiatry 1994; 151: 979-86
2. Paykel ES, Priest RG. Recognition and management of depression in general practice: consensus statement. BMJ 1992 Nov 14; 305: 1198-202
3. British National Formulary No. 33. London: The Pharmaceutical Press, 1997 Mar: 172-81
4. rd ed. Montvale NJ: Medical Economics, 1997
5. Davis R, Whittington R, Bryson H. Nefazodone: a review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997 Apr; 53 (4): 608-36
6. A place on the formulary for SSRIs in the treatment of depression. Drug Ther Perspect 1996; 8 (6): 13-6
7. Venlafaxine: another option in major depression. Drug Ther Perspect 1995; 5 (12): 1-4
8. Paroxetine in depression: improved tolerability over TCAs may offset higher acquisition costs. Drug Ther Perspect 1994; 3 (5): 5-7
9. D'Amico MF, Roberts DL, Robinson DS, et al. Placebo-controlled dose-ranging trial designs in phase II development of nefazodone. Psychopharmacol Bull 1990; 26 (1): 147-50
10. Marcus RN, Mendels J. Nefazodone in the treatment of severe, melancholic, and recurrent depression. J Clin Psychiatry 1996; 57 Suppl. 2: 19-23
11. Baldwin DS, Hawley CJ, Abed RT, et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 1996; 57 Suppl. 2: 46-52
12. Feiger AD, Bielski RD, Bremner JD, et al. Efficacy of nefazodone in continuation treatment of depression [abstract no. NR371]. 149th Meeting of the American Psychiatric Association; 1996 May 4-9; New York, 168-169.
13. Anton SF, Robinson DS, Roberts DL, et al. Long-term treatment of depression with nefazodone. Psychopharmacol Bull 1994; 30(2): 165-9
14. Robinson DS, Roberts DL, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry 1996; 57 Suppl. 2: 31-8
15. Lader MH. Tolerability and safety: essentials in antidepressant pharmacotherapy. J Clin Psychiatry 1996; 57 Suppl. 2: 39-44
16. Bristol-Myers Squibb. Nefazodone prescribing information. Princeton, New Jersey, USA, 1996
17. Aronoff GM. Trazodone associated with priapism [letter]. Lancet 1984 Apr 14; 1: 856
18. von Moltke LL, Greenblatt DJ, Schmider J, et al. Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995; 29 Suppl. 1: 33-44
19. Revicki DA, Brown RE, Palmer W, et al. Modelling the cost effectiveness of antidepressant treatment in primary care. Pharmacoeconomics 1995 Dec; 8: 524-40
20. Anton SF, Revicki DA. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone. Psychopharmacol Bull 1995; 31 (2): 249-58
21. Montgomery SA, Brown RE, Clark M. Economic analysis of treating depression with nefazodone v. imipramine. Br J Psychiatry 1996 Jun; 168: 768-71
22. Thase ME, Sullivan LR. Relapse and recurrence of depression: a practical approach for prevention. CNS Drugs 1995; 4 (4): 261-77
23. Frank E, Prien RF, Jarrett RB, et al. Conceptualisation and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse and recurrence. Arch Gen Psychiatry 1991; 48: 851-5